CN114555593A - 作为parg抑制剂的4-取代的吲哚和吲唑磺酰胺衍生物 - Google Patents
作为parg抑制剂的4-取代的吲哚和吲唑磺酰胺衍生物 Download PDFInfo
- Publication number
- CN114555593A CN114555593A CN202080065861.1A CN202080065861A CN114555593A CN 114555593 A CN114555593 A CN 114555593A CN 202080065861 A CN202080065861 A CN 202080065861A CN 114555593 A CN114555593 A CN 114555593A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- group
- hydrogen
- compound
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962903438P | 2019-09-20 | 2019-09-20 | |
| US62/903,438 | 2019-09-20 | ||
| PCT/US2020/051486 WO2021055744A1 (en) | 2019-09-20 | 2020-09-18 | 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114555593A true CN114555593A (zh) | 2022-05-27 |
Family
ID=72744866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080065861.1A Pending CN114555593A (zh) | 2019-09-20 | 2020-09-18 | 作为parg抑制剂的4-取代的吲哚和吲唑磺酰胺衍生物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220389003A1 (enExample) |
| EP (1) | EP4031249A1 (enExample) |
| JP (2) | JP2022548690A (enExample) |
| KR (1) | KR20220066922A (enExample) |
| CN (1) | CN114555593A (enExample) |
| AU (1) | AU2020348489A1 (enExample) |
| BR (1) | BR112022004624A2 (enExample) |
| CA (1) | CA3147493A1 (enExample) |
| IL (1) | IL291436A (enExample) |
| MX (1) | MX2022003276A (enExample) |
| TW (1) | TWI873187B (enExample) |
| WO (1) | WO2021055744A1 (enExample) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024017306A1 (zh) * | 2022-07-19 | 2024-01-25 | 苏州信诺维医药科技股份有限公司 | 含硫杂芳环化合物、其药物组合物及其用途 |
| CN118459452A (zh) * | 2024-07-10 | 2024-08-09 | 苏州国匡医药科技有限公司 | 一种多聚adp核糖水解酶抑制剂及其应用 |
| WO2024254990A1 (zh) * | 2023-06-16 | 2024-12-19 | 上海璎黎药业有限公司 | 一种杂芳环结构化合物、其药物组合物及应用 |
| WO2025067464A1 (zh) * | 2023-09-28 | 2025-04-03 | 杭州圣域生物医药科技有限公司 | 杂芳基化合物、其中间体、制备方法和应用 |
| WO2025087409A1 (zh) * | 2023-10-26 | 2025-05-01 | 上海齐鲁制药研究中心有限公司 | Parg抑制剂 |
| WO2025098445A1 (zh) * | 2023-11-07 | 2025-05-15 | 南京同诺康医药科技有限公司 | Parg抑制剂及其制备方法和用途 |
| WO2025108225A1 (zh) * | 2023-11-20 | 2025-05-30 | 上海复星医药（集团）股份有限公司 | 作为parg抑制剂的含氮三环衍生物 |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
| EP4413000A1 (en) | 2021-10-04 | 2024-08-14 | FoRx Therapeutics AG | N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer |
| AU2022359801A1 (en) | 2021-10-04 | 2024-02-01 | Forx Therapeutics Ag | Parg inhibitory compounds |
| WO2023154913A1 (en) * | 2022-02-14 | 2023-08-17 | Arase Therapeutics Inc. | Inhibitors of parg |
| JP2025509180A (ja) * | 2022-03-04 | 2025-04-11 | 上海瓔黎薬業有限公司 | 五員ヘテロアリール環構造含有化合物、その医薬組成物及び使用 |
| WO2023175184A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| WO2023175185A1 (en) | 2022-03-17 | 2023-09-21 | Forx Therapeutics Ag | 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer |
| WO2023183850A1 (en) * | 2022-03-23 | 2023-09-28 | Ideaya Biosciences, Inc. | Piperazine substituted indazole compounds as inhibitors of parg |
| CN117157299B (zh) * | 2022-04-28 | 2024-05-28 | 北京丹擎医药科技有限公司 | 三环杂环衍生物及其组合物和应用 |
| WO2023224998A1 (en) * | 2022-05-17 | 2023-11-23 | 858 Therapeutics, Inc. | Inhibitors of parg |
| JP2025522274A (ja) | 2022-05-17 | 2025-07-15 | ８５８ セラピューティクス，インコーポレーテッド | Ｐａｒｇの阻害剤 |
| WO2024002284A1 (zh) * | 2022-06-29 | 2024-01-04 | 杭州圣域生物医药科技有限公司 | 五元并六元含氮化合物、其中间体、制备方法和应用 |
| EP4311829A1 (en) | 2022-07-28 | 2024-01-31 | Nodus Oncology Limited | Substituted bicyclic heteroaryl sulfonamide derivatives for the treatment of cancer |
| WO2024074497A1 (en) | 2022-10-03 | 2024-04-11 | Forx Therapeutics Ag | Parg inhibitory compound |
| JP2025533274A (ja) * | 2022-10-13 | 2025-10-03 | ハンミ ファーマシューティカルズ カンパニー リミテッド | Ｙａｐ－ｔｅａｄ相互作用を阻害するための新規なヘテロ二環式化合物及びそれを含む薬学的組成物 |
| WO2024148280A1 (en) | 2023-01-06 | 2024-07-11 | Ideaya Biosciences, Inc. | Treatment of er+ breast cancer comprising homologous recombination deficiency using parc inhibitor |
| WO2024173234A1 (en) * | 2023-02-13 | 2024-08-22 | Arase Therapeutics Inc. | Inhibitors of parg |
| WO2024173530A1 (en) * | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted pyrazolo/imidazo pyridine compounds |
| WO2024173524A1 (en) * | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted benzimidazole compounds |
| WO2024173453A1 (en) * | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted imidazopyridine compounds |
| WO2024173514A1 (en) * | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Amide and ester-substituted imidazopyridine compounds |
| WO2024209035A1 (en) | 2023-04-05 | 2024-10-10 | Forx Therapeutics Ag | Parg inhibitory compounds |
| WO2024211506A1 (en) | 2023-04-05 | 2024-10-10 | Ideaya Biosciences, Inc. | Combination therapy comprising a parg inhibitor and a topoisomerase inhibitor for treating cancer |
| CN121002021A (zh) * | 2023-04-27 | 2025-11-21 | 北京丹擎医药科技有限公司 | 三环杂环衍生物及其组合物和应用 |
| WO2025046148A1 (en) | 2023-09-01 | 2025-03-06 | Forx Therapeutics Ag | Novel parg inhibitors |
| TW202528308A (zh) * | 2023-09-20 | 2025-07-16 | 美商愛德亞生物科學公司 | Parg抑制劑 |
| WO2025064750A1 (en) | 2023-09-20 | 2025-03-27 | Ideaya Biosciences, Inc. | Combination therapy with a parg inhibitor |
| WO2025072544A1 (en) * | 2023-09-27 | 2025-04-03 | Ideaya Biosciences, Inc. | Sulfonamino indazole compounds as inhibitors of parg |
| WO2025073870A1 (en) | 2023-10-03 | 2025-04-10 | Forx Therapeutics Ag | Parg inhibitory compound |
| CN119859145A (zh) * | 2023-10-20 | 2025-04-22 | 上海璎黎药业有限公司 | 一种杂芳环磺酰胺结构化合物、其药物组合物及应用 |
| WO2025087941A1 (en) | 2023-10-23 | 2025-05-01 | Universite De Geneve | Parg inhibitors in combination with parp inhibitors and uses thereof |
| WO2025093755A1 (en) | 2023-11-01 | 2025-05-08 | Forx Therapeutics Ag | Novel parc inhibitors |
| WO2025111339A1 (en) * | 2023-11-21 | 2025-05-30 | 858 Therapeutics, Inc. | Treatment of cancer with a parg inhibitor |
| TW202529739A (zh) * | 2023-11-22 | 2025-08-01 | 美商858療法股份有限公司 | Parg之抑制劑 |
| WO2025133396A1 (en) | 2023-12-22 | 2025-06-26 | Forx Therapeutics Ag | Novel bicyclo heteroaryl parg inhibitors |
| WO2025133191A1 (en) * | 2023-12-22 | 2025-06-26 | Genecode | Novel sulfonamides or sulfones and their use as neuroprotective and/or neurorestorative agents |
| WO2025229549A1 (en) * | 2024-04-30 | 2025-11-06 | Satyarx Pharma Innovations Pvt Ltd | Novel heterocyclic compounds as inhibitors of parg |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab, Soedertaelje | 4-anilinochinazolin derivate |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| EE05345B1 (et) | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Kinasoliini derivaadid angiogeneesi inhibiitoritena |
| CN1431999A (zh) | 2000-05-31 | 2003-07-23 | 阿斯特拉曾尼卡有限公司 | 具有血管损伤活性的吲哚衍生物 |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| JP2004502766A (ja) | 2000-07-07 | 2004-01-29 | アンギオジェン・ファーマシューティカルズ・リミテッド | 血管損傷剤としてのコルヒノール誘導体 |
| RU2003103603A (ru) | 2000-07-07 | 2004-08-20 | Энджиоджен Фармасьютикалз Лимитед (Gb) | Производные колхинола в качестве ингибиторов ангиогенеза |
| CA2834101A1 (en) * | 2011-01-07 | 2012-07-12 | Taiho Pharmaceutical Co., Ltd. | Novel indole or indazole derivative or salt thereof |
| MA41140A (fr) * | 2014-12-12 | 2017-10-17 | Cancer Research Tech Ltd | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg |
| MA41179A (fr) * | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
| EP3697777A1 (en) * | 2017-10-19 | 2020-08-26 | eFFECTOR Therapeutics, Inc. | Benzimidazole-indole inhibitors of mnk1 and mnk2 |
| EP3870575B1 (en) * | 2018-10-25 | 2023-03-29 | ViiV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| WO2023183850A1 (en) * | 2022-03-23 | 2023-09-28 | Ideaya Biosciences, Inc. | Piperazine substituted indazole compounds as inhibitors of parg |
-
2020
- 2020-09-18 CN CN202080065861.1A patent/CN114555593A/zh active Pending
- 2020-09-18 KR KR1020227012903A patent/KR20220066922A/ko active Pending
- 2020-09-18 US US17/761,935 patent/US20220389003A1/en active Pending
- 2020-09-18 MX MX2022003276A patent/MX2022003276A/es unknown
- 2020-09-18 TW TW109132483A patent/TWI873187B/zh active
- 2020-09-18 EP EP20786137.8A patent/EP4031249A1/en active Pending
- 2020-09-18 AU AU2020348489A patent/AU2020348489A1/en active Pending
- 2020-09-18 WO PCT/US2020/051486 patent/WO2021055744A1/en not_active Ceased
- 2020-09-18 BR BR112022004624A patent/BR112022004624A2/pt unknown
- 2020-09-18 CA CA3147493A patent/CA3147493A1/en active Pending
- 2020-09-18 JP JP2022517374A patent/JP2022548690A/ja not_active Ceased
-
2022
- 2022-03-16 IL IL291436A patent/IL291436A/en unknown
-
2024
- 2024-11-01 JP JP2024193094A patent/JP7781244B2/ja active Active
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024017306A1 (zh) * | 2022-07-19 | 2024-01-25 | 苏州信诺维医药科技股份有限公司 | 含硫杂芳环化合物、其药物组合物及其用途 |
| WO2024254990A1 (zh) * | 2023-06-16 | 2024-12-19 | 上海璎黎药业有限公司 | 一种杂芳环结构化合物、其药物组合物及应用 |
| WO2025067464A1 (zh) * | 2023-09-28 | 2025-04-03 | 杭州圣域生物医药科技有限公司 | 杂芳基化合物、其中间体、制备方法和应用 |
| WO2025087409A1 (zh) * | 2023-10-26 | 2025-05-01 | 上海齐鲁制药研究中心有限公司 | Parg抑制剂 |
| WO2025098445A1 (zh) * | 2023-11-07 | 2025-05-15 | 南京同诺康医药科技有限公司 | Parg抑制剂及其制备方法和用途 |
| WO2025108225A1 (zh) * | 2023-11-20 | 2025-05-30 | 上海复星医药（集团）股份有限公司 | 作为parg抑制剂的含氮三环衍生物 |
| CN118459452A (zh) * | 2024-07-10 | 2024-08-09 | 苏州国匡医药科技有限公司 | 一种多聚adp核糖水解酶抑制剂及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220389003A1 (en) | 2022-12-08 |
| TWI873187B (zh) | 2025-02-21 |
| JP2022548690A (ja) | 2022-11-21 |
| TW202120501A (zh) | 2021-06-01 |
| IL291436A (en) | 2022-05-01 |
| MX2022003276A (es) | 2022-04-11 |
| CA3147493A1 (en) | 2021-03-25 |
| WO2021055744A1 (en) | 2021-03-25 |
| EP4031249A1 (en) | 2022-07-27 |
| AU2020348489A1 (en) | 2022-05-05 |
| JP2025016684A (ja) | 2025-02-04 |
| BR112022004624A2 (pt) | 2022-05-31 |
| JP7781244B2 (ja) | 2025-12-05 |
| KR20220066922A (ko) | 2022-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114555593A (zh) | 作为parg抑制剂的4-取代的吲哚和吲唑磺酰胺衍生物 | |
| KR102616970B1 (ko) | Ｐｒｍｔ５-매개성 질환의 치료 또는 예방에 유용한 화합물 | |
| US8003649B2 (en) | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions-155 | |
| EP3080121B1 (en) | Fused tricyclic benzimidazoles derivatives as modulators of tnf activity | |
| AU2012288626C1 (en) | 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as EGFR modulators useful for treating cancer | |
| EP3630749B1 (en) | 2-quinolone derived inhibitors of bcl6 | |
| KR102604942B1 (ko) | 증식성 장애의 치료에 사용하기 위한 트리사이클릭 화합물 | |
| WO2024173453A1 (en) | Heteroaryl-substituted imidazopyridine compounds | |
| WO2024173524A1 (en) | Heteroaryl-substituted benzimidazole compounds | |
| WO2024173514A1 (en) | Amide and ester-substituted imidazopyridine compounds | |
| CN114981270B (zh) | Mll1抑制剂和抗癌剂 | |
| AU2021410926A9 (en) | Tetrahydrothienopyrimidinesulfonamide compounds | |
| WO2024052702A1 (en) | Novel compounds as ck2 inhibitors | |
| WO2024052692A1 (en) | Novel compounds as ck2 inhibitors | |
| HK40082765A (en) | 2-(2,4,5-substituted-anilino)pyrimidine compounds as egfr modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |